The American College of Rheumatology developed guidelines for the management of gout, including use of urate-lowering therapy, flare treatment, and lifestyle and medication recommendations.
Avion Pharmaceuticals announced the launch of Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults. Gloperba is a ready-to-use solution for oral administration containing 0.12mg/mL of colchicine. The approval was based on evidence from published literature supporting the efficacy of colchicine in patients with chronic gout. In 2 randomized clinical trials, treatment with…
Allopurinol and febuxostat were found to be associated with a higher risk of hypersensitivity reactions when compared to colchicine, according to the results of a recently published population-based study.
Compared with chlorthalidone and lisinopril, amlodipine associated with lower risk for gout.
Compared with intravenous hydrocortisone, IV methylprednisolone appears to be more beneficial as a pre-infusion prophylaxis therapy in patients receiving pegloticase, according to the findings of a recently published review.
Researchers assessed the demographics associated with the admission of acute myocardial infarction and evaluated the differences between rheumatoid arthritis and gout and osteoarthritis.
The following article is a part of conference coverage from the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, being held in Atlanta, Georgia. The team at MPR will be reporting on the latest news and research conducted by leading experts in rheumatology. Check back for more from the 2019 ACR/ARP Annual…
Opioids are commonly prescribed for acute gout management following discharge from the emergency department.
The Food and Drug Administration has approved Gloperba (colchicine; ROMEG Therapeutics) Oral Solution for the prophylaxis of gout flares in adults. It is the first liquid formulation of colchicine to be approved by the FDA for this indication.
The prescribing information for Uloric (febuxostat; Takeda) is being updated to include a Boxed Warning regarding an increased risk of cardiovascular (CV) death and all-cause mortality in patients treated with the gout drug.
